Article
CD209 promoter polymorphisms associate with HCV infection and pegylated-interferon plus ribavirin treatment response.
Molecular immunology - 1 Aug 2016
Zupin Luisa, Polesello Vania, Alberi Giulia, Moratelli Giulia, Crocè Saveria Lory, Masutti Flora, Pozzato Gabriele, Crovella Sergio, Segat Ludovica
Abstract excerpt
Hepatitis C is a severe liver disease caused by hepatitis C virus that could persist in the host causing progression towards chronic disease in about 80% of the cases. Pegylated-interferon plus ribavirin was the gold standard therapy, however treatment's response was quite variable among individuals and different host/viral factors may play a role in disease outcome. The cluster of differentiation 209 (CD209...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
